Australian PMOS advocates call for subsidised access to weight-loss medicines

The Polyendrocrine Metabolic Ovarian Syndrome Association of Australia (POSAA) is calling for GLP-1 weight-loss medicines to be subsidised for people with PMOS through Australia's Pharmaceutical Benefits Scheme. The request, reported by the Guardian on 9 October 2026 UTC, matters to patients who may face substantial private costs; it does not amount to a government decision to fund the medicines for the condition.

POSAA spokesperson Lorna Berry told the Guardian that some women with PMOS already cannot access the medicines because they can cost several hundred dollars a month. Berry, who was diagnosed at 32, also called for funding for evidence-based research. She said access should be equitable regardless of where people live or where they were born.

Why POSAA is seeking PBS coverage for PMOS

PMOS, formerly known as polycystic ovarian syndrome, affects about one in eight women, according to the Guardian. Its possible symptoms include irregular periods, excess body and facial hair, weight gain and hair thinning. The report describes it as a lifelong condition without a cure and says it is associated with increased risks of type 2 diabetes, cardiovascular disease and endometrial cancer. The subsidy call concerns access for people living with that condition, rather than a change to its treatment guidelines.

The Guardian reports that Australia's Therapeutic Goods Administration has not specifically approved GLP-1 medicines to treat PMOS, although some patients are prescribed them off-label. GLP-1 medicines mimic a naturally occurring hormone that helps regulate blood sugar and reduce hunger. Their use for PMOS is therefore a distinct question from the conditions for which particular products already have approval or public funding.

QENDO, an organisation advocating for people affected by PMOS and other women's health conditions, also pointed to the evidence gap. Acting chief executive Kate Fisher told the Guardian that interest in GLP-1 medicines is growing, particularly for people dealing with metabolic complications and weight-management challenges. She said further research is needed to establish long-term effectiveness and safety specifically for PMOS. Neither group's comments establish that a subsidy application for PMOS has been accepted.

What the separate Wegovy subsidy process shows

Existing PBS arrangements do not establish coverage for PMOS. The Guardian reports that Ozempic is PBS-listed for diabetes treatment only. It says Ozempic and Wegovy both contain semaglutide, with Wegovy supplied at a higher dose. A proposed Wegovy listing is moving through a separate process concerning obesity and cardiovascular disease; that process should not be read as approval of POSAA's request.

A PBS medicine-status record, current as at 1 October 2026, identifies a Wegovy submission for people with established cardiovascular disease and obesity. It records that the Pharmaceutical Benefits Advisory Committee recommended the submission after its 5 November 2025 meeting. Yet the record says complete documentation had not been accepted, listing arrangements and government processes had not commenced, and a PBS listing had not occurred. Those recorded steps show that a committee recommendation alone does not put this separate listing into effect.

The Guardian also reports that the committee is due to consider Novo Nordisk's revised proposal for an obesity listing the following month. Novo Nordisk told the newspaper it was continuing to work with the Department of Health on a Wegovy PBS listing for eligible Australians living with obesity. The reported meeting timetable concerns that proposal; it supplies no timetable for PBS coverage of GLP-1 medicines for PMOS.

What remains unresolved for patients

For people with PMOS, the immediate issues are affordability, the absence of a PMOS-specific TGA approval described by the Guardian and the unanswered question of long-term benefit and safety for this use. Berry's call sets out what POSAA wants, while Simonis and Fisher describe why clinical evidence matters to any wider access debate. The available PBS status record documents a different Wegovy indication, so it cannot establish that public funding for PMOS is imminent.